Some reports have suggested that white-coat hypertension (WCH) is associated with some features of the metabolic syndrome (MetS). These metabolic disturbances, instead of WCH per se, may potentially explain the greater extent of end-organ damage sometimes observed in WCH subjects (WCHs) when compared to normotensive individuals (NTs). The aim of the present cross-sectional study was to compare left ventricular (LV) structure and function in three groups of subjects: WCHs with MetS, WCHs without MetS and NTs. A total of 145 WCHs, 35% of whom had MetS, were enrolled. As controls, 35 NTs were also studied. In all subjects, routine blood chemistry, echocardiographic examination and 24-h ambulatory blood pressure monitoring were performed. When compared with WCHs without MetS, those with MetS showed higher LV mass indexed by height elevated by a power of 2.7 (LVMH ; P ¼ 0.004). Moreover, the E-wave deceleration time was longer in WCHs with MetS than in those without it (236.2766.4 vs 200.5730.8 ms; Po0.0001). The relationship of MetS with LVMH 2.7 was confirmed in multivariate regression models. Our results seem to suggest that MetS may have a deleterious influence on LV structure and function in WCH. However, WCH, being associated with an increased LV mass, also in subjects without MetS, may not be considered as an innocuous phenomenon.
Introduction
White-coat hypertension (WCH), also called 'isolated office or clinic hypertension', is defined as the occurrence of blood pressure (BP) values X140/ 90 mm Hg when measured in the medical environment and within the normal range when recorded during daily life, by means of ambulatory BP monitoring or home BP measurements. 1 The prognostic significance of WCH has been widely explored in the last years, but it is still a matter of debate. 1, 2 Indeed, the studies that evaluated the effects of WCH on hypertensive target organ damage and on the occurrence of future cardiovascular events yielded conflicting results. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] It has long been recognized that hypertension tends to cluster with various anthropometric and metabolic abnormalities, including elevated triglycerides, reduced high-density lipoprotein (HDL) cholesterol, glucose intolerance, abdominal obesity and insulin resistance, which are the main features of the metabolic syndrome (MetS). MetS, which may precede the appearance of sustained hypertension, contributes to the development of hypertensive target organ damage and atherosclerotic diseases. [18] [19] [20] Several studies reported a greater prevalence of some features of MetS in white-coat hypertensive subjects (WCHs) than in normotensive subjects (NTs). [9] [10] 12, 21 It has been suggested that these metabolic disturbances, instead of WCH per se, may explain the results obtained in those investigations in which a greater extent of end-organ damage and an increased cardiovascular risk were observed in WCHs when compared to NTs. [22] [23] The aim of the present cross-sectional study was to compare left ventricular (LV) structure and function, assessed by Doppler echocardiography, in three groups of subjects: WCHs with MetS, WCHs without MetS and NTs.
Methods
The study population was selected from the hypertensive patients referred to our outpatient hypertension clinic because of office BP higher than 140/ 90 mm Hg in at least three visits to a doctor's office, and in which routine blood chemistry, 24-h ambulatory blood pressure monitoring (ABPM) and Doppler echocardiographic examination of good quality were obtained. One hundred and forty-five patients with clinic BP X140/90 mm Hg and daytime ambulatory BPo130/80 mm Hg were considered as WCHs 17 and were enrolled in this study. In all these subjects, office hypertension was diagnosed within the previous 2 years. From the hospital staff we also recruited 35 clinically NTs matched for age, gender, smoking habit, level of physical activity and body mass index (BMI) with the subgroup of WCHs without MetS. Moreover, none of the participants to this study was an athlete and their physical activity was very low, so that they may be considered as sedentary subjects. All the patients have never been previously treated with antihypertensive drugs.
Exclusion criteria were secondary or malignant hypertension, heart failure, positive history or clinical signs of ischaemic heart disease, cerebrovascular disease, renal insufficiency (serum creatinine 41.5 mg/dl in men and 41.4 mg/dl in women), overt proteinuria, major non-cardiovascular diseases, dyslipidaemia requiring pharmacological treatment and known diabetes or fasting glycaemia X126 mg/dl.
Written informed consent was obtained from each subject and the study was approved by the local review board.
Study design
In all subjects, careful clinical history and physical examination were performed. Body weight, height and waist circumference were measured by a nurse, and clinic BP was recorded by a doctor. The BP was measured in sitting and in supine position. In each position the BP was recorded in triplicate on the same arm, after 5 min of rest, with a mercury sphygmomanometer. Because no significant difference was observed between the averages of sitting and supine position, in line with the major international hypertension guidelines, only sitting BPs were reported in our paper.
Additionally, after an overnight fast of at least 10 h, blood samples were drawn to perform routine blood chemistry. Furthermore, 24-h ABPM and echocardiographic study were carried out.
Measurements
Determination of routine biochemical parameters was performed with standard techniques by using an autoanalyser (Boehringer Mannheim for Hitachi System 911, Germany). Low-density lipoprotein (LDL) cholesterol was calculated by the Friedwald formula.
MetS was defined according to the criteria proposed by the National Cholesterol Education Program Adult Treatment Panel III , with the minor modifications recommended by the 2005 American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. 18 Therefore, individuals were classified as having the MetS if they had, in addition of hypertension, two or more of the following abnormalities: HDL o40 mg/dl in men or 50 mg/dl in women; fasting glucose between 100 and 125 mg/dl; triglycerides 4150 mg/dl; and waist circumference 4102 cm in men or 488 cm in women.
A portable, non-invasive SpaceLabs 90207 recorder (Redmond, WA, USA) performed the 24-h ABPM. BP readings were performed automatically at 15 min intervals during the day (from 0700 to 2200 hours) and at 20 min intervals during night-time resting (from 2200 to 0700 hours). The time periods were standardized according to the time at which the patients rose and retired. The reading, editing and analysis of the data provided by the recorders were carried out by the SpaceLabs ABP90209 interface, version 2.40.23. Systolic readings greater than 260 mm Hg or less than 70 mm Hg, diastolic readings higher than 150 mm Hg or less than 40 mm Hg and pulse pressure readings above 150 mm Hg or below 20 mm Hg were automatically discarded.
Only records with more than 80% of valid data were accepted. M-mode echocardiography, guided by a two-dimensional echocardiography, was performed with the patient maintained in a partial left decubitus position, using an Acuson Sequoia 512 (Siemens, Mountain View, CA, USA).
M-mode measurements were taken at end diastole and end systole in line with the American Society of Echocardiography (ASE) recommendations. 24 Only those frames with optimal visualization of interfaces and showing simultaneous visualization of septum, LV internal diameter and posterior wall were used for readings. Myocardial relative wall thickness was calculated as twice posterior wall in diastole divided by internal diameter, and was used as an estimate of LV geometry.
LV mass was determined using the ASE corrected cube-formula:
It was indexed by both body surface area (LVMI) and by height elevated by a power of 2.7 (LVMH 2.7 ), as suggested by de Simone et al., 26 to provide a more stringent allowance for obesity (LVMH 2.7 ). A cut-off point of 51 g/m 2.7 in either gender was set to separate normal from left ventricular hypertrophy (LVH), because this partition value is supported by prognostic evidence. 27 LV shortening at the endocardium and mid-wall were used as estimates of LV chamber and myocardial systolic function. Fractional shortening at the endocardium was calculated as the difference between the end-diastolic and end-systolic internal diameter divided by the end-diastolic diameter and then multiplied by 100. Myocardial function was assessed as mid-wall circumferential shortening and calculated using a two-shell cylindrical model, as described previously. 28 The pulsed-Doppler examination of transmitral blood flow was performed from the apical fourchamber view by using a 2.5 MHz transducer, with the sample at the level of the tip of mitral valve leaflets. The parameters measured from the Doppler waveform were the early filling peak velocity (E wave), the late filling peak velocity (A wave) and their ratio (E/A ratio). Moreover, the time of E velocity deceleration was measured as the interval between the peak E velocity and the point at which the descending segment of the E wave, or its asymptote, crosses the zero-velocity line.
Echocardiographic data are expressed as the average of five consecutive cardiac cycles. Images were read blindly by a single cardiologist, unaware of the patient's clinical characteristics.
In our laboratory, the mean intra-observer variability was 8.6% for LV mass and 7.8 and 8.9% respectively for peak velocities in early and late filling.
Statistics
Continuous variables were given as means7s.d. We used one-way analysis of variance to evaluate differences in means. Comparisons between subgroups (WCHs with MetS versus WCHs without MetS and these latter versus NTs) were performed, if the overall F test was significant, by using the independent-sample Student's t-test with the Bonferroni correction. Proportional differences between groups were assessed by the w 2 test, with Yates' correction.
Adjustment for age, gender and other potential confounders was carried out, where appropriate, by analysis of covariance (ANCOVA) and multiple logistic regression analysis.
Univariate and multivariate associations of LV mass with other variables were assessed by the Pearson correlation coefficients and stepwise multiple linear regression analyses. Initially, age, gender and all the other variables associated with LV mass in univariate analyses were included in the multiple regression models. Subsequently, we ran the models again, adding MetS as a dummy variable, after the exclusion of the parameters not associated with LV mass in the preliminary analyses.
The null hypothesis was rejected at a two-tailed Pp0.05.
The statistical analyses were performed using the SYSTAT DATA software package, version 11 (Systat, Richmond, CA, USA).
Results
The study population consisted of 145 patients (mean age 43.3712.5 years), 70 of whom were men. The prevalence of MetS was 35% (50/145). Table 1 gives demographic and clinical data of normotensive controls and of WCHs divided into two subgroups with and without MetS. As expected the values of all anthropometric and metabolic parameters used for the definition of MetS were significantly higher, and HDL cholesterol (HDLc) level was lower in WCH subjects with MetS, when compared to those without it. Furthermore, patients with MetS were older, had slightly higher total and LDL cholesterol levels and showed a greater proportion of women in comparison to the WCHs without MetS. The two groups with and without MetS did not differ in terms of smoking habits.
Demographic and clinical data of normotensive controls did not differ significantly from those of WCHs without MetS.
As presented in Table 2 , clinic systolic BP was higher in WCHs with MetS than in those without it. White-coat hypertension and metabolic syndrome G Mulè et al
All the other BP parameters were not different in the two groups with WCH. Clinic systolic and diastolic BP were higher and 24-h diastolic BPs were lower in WCHs without MetS than in normotensive controls.
Echocardiographic parameters of the three subgroups evaluated are reported in Table 3 . Participants with WCH and MetS exhibited significantly higher interventricular septum thickness (IVS) and LV mass, either normalized for BSA (LVMI) or for height 2.7 (LVMH 2.7 ) than WCHs without MetS (Figure 1 ). These differences remained still statistically significant even after adjustment, by ANCOVA, for age, gender and clinic systolic BP (P ¼ 0.03 for IVS, P ¼ 0.02 for LVMI and Po0.0001 for LVMH 2.7 , respectively). Prevalence of LV hypertrophy was also greater in MetS group. The increased probability of having LV hypertrophy, in subjects with MetS, remained significant, also taking into account age, gender and clinic systolic BP in multiple logistic regression analysis (odds ratio ¼ 1.89, 95% confidence interval 1.13-3.18; P ¼ 0.01).
Mid-wall fractional shortening (mwFS) was lower and E-wave deceleration time (Dec T) was longer in WCHs with MetS when compared to those without it, even after controlling for age, gender and clinic systolic BP (P ¼ 0.04 for mwFS and P ¼ 0.01 for Dec T, respectively).
When we compared the LV morphofunctional characteristics of WCHs without MetS with those of NTs, the former showed LV chamber diameter (Table 3) , LVMI and LVMH 2.7 higher than the latter (Figure 1) .
Univariate correlation analysis, conducted in the study population with WCH, revealed that LV mass indexed for height 2 .
White-coat hypertension and metabolic syndrome G Mulè et al of the 24-h ambulatory BP readings, did not significantly modify the results. The same was true when BMI was replaced by waist circumference. The regression coefficients b relating this latter measure of visceral adiposity to LVMH 2.7 were 0.32 (P ¼ 0.00002) in the multivariate model not including MetS and 0.25 (P ¼ 0.001) in the model including MetS.
Similar results were also obtained when obesity was introduced in the regression model as dichotomous rather than continuous variable. The standardized coefficients of regression b relating MetS to LVMH 2.7 were 0.20 (P ¼ 0.01) when obesity was expressed as BMI425 kg/m 2 ¼ 1 (being BMI p25 kg/ m 2 ¼ 0), and 0.22 (P ¼ 0.009) when obesity was identified on the basis of the waist girth (coded as 1 when waist circumference 4102 cm in men and 488 cm in women and coded as 0 when waist girth p102 cm in men and p88 cm in women).
Discussion
The main finding of the present study was the identification of a close association between MetS and some preclinical morphofunctional abnormalities of the left ventricle in subjects with WCH. These results confirm the negative impact of MetS on cardiac structure and function previously reported in general population and in globally considered hypertensive patients. [19] [20] It is well known that insulin resistance and the accompanying compensatory hyperinsulinemia are the pathophysiologic key features underlying the MetS. 18 Trophic effects of insulin on myocardial tissue in cell cultures and animal models have been demonstrated. Moreover, in some but not all human studies, an association between insulin and LV mass has been found. 20 Interestingly, in a recent study patients with WCH and LVH were more insulin-resistant than those without LVH. 29 Other potential biologic mediators of LV hypertrophy in subjects with MetS may be certain peptide hormones, such as angiotensin II and leptin, which are secreted by white adipose tissue. 20 Our findings also suggest that the clustering of features of MetS, frequently described in WCHs, may be at least in part responsible for the cardiac abnormalities, and probably for the increased cardiovascular risk displayed in some, but not all, series regarding subjects with WCH [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . On the other hand, the greater values of both LV mass and LV chamber diameter that we observed in WCHs without MetS when compared to those of normotensive controls, seem to indicate that WCH per se, independently of MetS, may not be innocuous for the heart. This highlights the clinical importance of office BP in hypertension and suggests that subjects with hyperreaction to stressful situations may develop initial changes of the left ventricle, even though their 24-h (or daytime) mean BP is normal. In this context, it has been demonstrated that periods of neurogenic pressor episodes without permanent hypertension can cause LV hypertrophy in dogs. 30 Therefore, it could be speculated that frequent BP peaks triggered by alerting reactions may contribute to the rise in long-term cardiovascular risk.
The importance of WCH has been increasingly recognized. In terms of target organ damage and cardiovascular risk WCH may not be exactly the same as sustained essential hypertension. Nevertheless, such patients are not quite 'normal' and cannot be discharged from medical attention. Indeed, at variance with several longitudinal studies with short follow-up periods, 13 in more recent reports with a longer duration of the follow-up, [15] [16] [17] a greater cardiovascular event rate was observed in WCHs than in NTs.
Recently, pooled data from four cohort studies from United States, Italy and Japan showed a trend to increasing stroke rate after the sixth year of follow-up in the group with WCH. Moreover, the corresponding hazard curve crossed that of the ambulatory hypertension group by the ninth year ), on the right, in white-coat hypertensives (WCHs) with and without metabolic syndrome (MetS) and in normotensive subjects (NTs 17 These findings raise some concerns about the long-term safety of WCH.
It is worth noting that our result was obtained using the more conservative threshold level of daytime ambulatory BP to identify the WCHs, that is o130/80 mm Hg. Indeed, the conflicting results of previous reports on subjects with WCH could be partially due to differences in the methods used to identify these patients. Labelling a subject as a WCHs implies the arbitrary identification of cutoffs of ambulatory BP, which differed markedly from author to author, ranging from 80 to 95 mm Hg for diastolic BP and from 130 to 140 mm Hg for systolic BP. 1, 2 Obviously, the use of higher limits for ambulatory BP results in higher frequencies of WCH individuals with end-organ damage. However, in previous investigations, such as the HARVEST (Hypertension and Ambulatory Recording Venetia Study) 3 and the PAMELA (Pressioni Arteriose Monitorate e Loro Associazioni) 4 studies, even when lower cutoffs of ambulatory BP were used, an association between WCH and left ventricular hypertrophy was found.
Several factors can account for the lack of association between cardiovascular abnormalities and WCH reported by previous studies. Some authors who concluded that white-coat hypertension is innocuous did not even include a normotensive control group in their study. The apparent inconsistency between data from different studies could be also due to the confounding influence of previous antihypertensive treatment that may minimize or eliminate the possible differences with the normotensive controls. Moreover, in several studies, small samples of patients were taken into account.
Some other aspects of our paper need to be discussed.
Even if an independent association between MetS and LV mass was documented in our study, it is important to note that obesity was associated with LV mass more powerfully than MetS in itself. This supports the likely benefit of weight management as an important therapeutic strategy in overweight individuals with the WCH.
In conclusion, the results of our study seem to suggest that MetS may have a deleterious influence on LV structure and function in white-coat hypertension. However, WCH, being associated with an increased LV mass, also in subjects without MetS, may not be considered as an innocuous phenomenon.
What is known about this topic K The prognostic significance of white-coat hypertension is still a matter of debate.
1,2
K The metabolic syndrome, even without overt diabetes, may contribute to the development of hypertensive cardiac damage and atherosclerotic diseases. [18] [19] [20] K Several studies reported a greater prevalence of some features of the metabolic syndrome in white-coat hypertensive subjects than in normotensive ones. 9, 10, 12, 21 What this study adds K The metabolic syndrome may have a deleterious influence on left ventricular structure and function in white-coat hy pertension. K White-coat hypertensive patients, even without metabolic syndrome, have greater left ventricular mass than normotensive subjects.
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